News | April 22, 2024
Vertex announces advancements of Suzetrigine in acute and neuropathic pain
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Breakthrough Therapy designation for pain associated with DPN granted by FDA
10th edition of the event is scheduled to be held during May 30-June 1 at Hitex, Hyderabad
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
Longest survival follow-up ever reported for immunotherapy treatment in this setting
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
The company plans to add 1700 beds by FY27 through the organic route
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
Subscribe To Our Newsletter & Stay Updated
